Angina, Unstable
Blood Cell Count
Dalteparin
Venous Thromboembolism
Venous Thrombosis

Dalteparin

Dalteparin sodium is a low molecular weight heparin (LMWH) medication used to manage venous thromboembolism (VTE), deep vein thrombosis (DVT), and ischemic complications of unstable angina and non-Q-wave myocardial infarction. The medication is derived from unfractionated heparin to form LMWH and is commonly administered as a subcutaneous injection. Symptoms of overdose necessitate urgent medical attention, with protamine sulfate as an antidote. Routine complete blood counts and stool occult blood tests are recommended during treatment with dalteparin, and patients with renal insufficiency require additional monitoring. Concomitant use of medications that affect coagulation may pose similar risks as other heparins. This activity provides comprehensive information about the mechanism of action, adverse event profile, and other key factors. The dosing strategies, pharmacokinetics, monitoring, drug-drug interactions, and contraindications are pertinent for interprofessional team members treating conditions when the agent is indicated. In particular, clinicians from emergency medicine, critical care, or hospitalists may be better equipped to manage a prevalent set of thromboembolic conditions.

Credit & MOC Details

Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.